1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Best-In-Class Or First-In-Class: CGRP Inhibitors Line Up To Win The Migraine Market

 
• By Mandy Jackson

Amgen will be the first biopharma company to seek approval for a CGRP inhibitor when it submits a BLA for FDA approval later in the second quarter, but Alder, Lilly, Teva and Allergan are in the running for best-in-class status to treat unmet needs in migraine and other headache markets.

Human brain illustrated with millions of small nerves - Conceptual 3d render

Companies developing new migraine therapies that inhibit calcitonin gene-related peptide (CGRP) or its receptor will test the first-in-class versus best-in-class struggle for market share over the next two years, as late-stage data are reported and applications for drug approvals are submitted.

Amgen Inc., as the only company that's reported Phase III data, is in the lead and plans to submit...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?